Exhibit 99.1
 
Contacts:
Melissa A. Waterhouse
Chief Executive Officer
(800) 227-1243, Ext 107
 
FOR IMMEDIATE RELEASE:
 
ABMC REPORTS THIRD QUARTER 2019 RESULTS
 
Kinderhook, N.Y., November 14, 2019
– American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and nine months ended September 30, 2019.
 
Chief Executive Officer Melissa A. Waterhouse stated, “Sales in the third quarter of 2019 increased slightly when compared to the third quarter of 2018. This is primarily due to increased contract business; an area we previously indicated would positively impact sales in the second half of 2019.”
 
Waterhouse added, “Operating expenses are down once again due to our concerted efforts to control expenditures. This, along with increased sales, enabled us to decrease our operating loss and our net loss in the third quarter of 2019 when compared to the third quarter of 2018. From a liability perspective, we are currently in discussions to extend and/or refinance our debt that matures in 2020. Looking forward, we are hopeful that orders from new customers and potential new business currently in our pipeline will enable us to continue reporting increased sales and improved results from operations in the fourth quarter of 2019.”
 
Financial Highlights
 
 Net sales in the third quarter of 2019 were $895,000, compared to net sales of $878,000 in the third quarter of 2018, an increase of $17,000, or 1.9%. Net sales in the nine months ended September 30, 2019 were $2,775,000, compared to net sales of $2,988,000 in the nine months ended September 30, 2018, a decrease of $213,000, or 7.1%.
 
 Operating loss was $81,000 in the third quarter of 2019, compared to an operating loss of $132,000 in the third quarter of 2018. Operating loss was $410,000 in the nine months ended September 30, 2019, compared to an operating loss of $413,000 in the nine months ended September 30, 2018.
 
 Net loss was $144,000, or $(0.00) per share, in the third quarter of 2019, compared to net loss of $202,000, or $(0.01) per share, in the third quarter of 2018. Net loss was $440,000, or $(0.01) per share, for the nine months ended September 30, 2019, compared to net loss of $615,000, or $(0.02) per share, in the nine months ended September 30, 2018.
 
For more information on ABMC or its drug testing products, please visit www.abmc.com.
 
About American Bio Medica Corporation
 
American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
 
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company's annual report on Form 10-K for the year ended December 31, 2018, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
 
 (financial tables follow)
 
 
1
 
 
AMERICAN BIO MEDICA CORPORATION
Condensed Statements of Operations
(unaudited)
 
 
 
For the three
 
 
For the three
 
 
For the nine
 
 
For the nine
 
 
 
months ended
 
 
months ended
 
 
months ended
 
 
months ended
 
 
 
September 30,
2019
 
 
September 30,
2018
 
 
September 30,
2019
 
 
September 30,
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
 $895,000 
 $878,000 
 $2,775,000 
 $2,988,000 
Cost of goods sold
  536,000 
  514,000 
  1,805,000 
  1,815,000 
Gross profit
  359,000 
  364,000 
  970,000 
  1,173,000 
 
    
    
    
    
Operating expenses:
    
    
    
    
Research and development
  23,000 
  20,000 
  62,000 
  64,000 
Selling and marketing
  131,000 
  125,000 
  350,000 
  435,000 
General and administrative
  286,000 
  351,000 
  968,000 
  1,087,000 
Total operating expenses
  440,000 
  496,000 
  1,380,000 
  1,586,000 
 
    
    
    
    
Operating loss
  (81,000)
  (132,000)
  (410,000)
  (413,000)
 
    
    
    
    
Other income / (expense)
  (63,000)
  (70,000)
  (28,000)
  (200,000)
 
    
    
    
    
Net loss before tax
  (144,000)
  (202,000)
  (438,000)
  (613,000)
 
    
    
    
    
Income tax benefit / (expense)
  0 
  0 
  (2,000)
  (2,000)
 
    
    
    
    
Net loss
 $(144,000)
 $(202,000)
 $(440,000)
 $(615,000)
 
    
    
    
    
Basic & diluted loss per common share
 $(0.00)
 $(0.01)
 $(0.01)
 $(0.02)
 
    
    
    
    
Weighted average shares outstanding – basic and diluted
  32,545,776 
  30,241,313 
  32,479,123 
  30,001,598 
 
(Condensed Balance Sheets follow)
 
 
2
 
 
American Bio Medica Corporation
Condensed Balance Sheets
 
 
 
September 30,
 
 

 
 
 
2019
(unaudited)
 
 
December 31,
2018
 
ASSETS
 
 
 
 
 
 
Current Assets
 
 
 
 
 
 
Cash and cash equivalents
 $15,000 
 $113,000 
Accounts receivable, net of allowance for doubtful accounts of $34,000 at September 30, 2019 and $36,000 at December 31, 2018
  492,000 
  452,000 
Inventory, net of allowance of $286,000 at September 30, 2019 and $268,000 at December 31, 2018
  890,000 
  1,019,000 
Prepaid expenses and other current assets
  24,000 
  29,000 
Right of use asset – operating leases
  12,000 
  0 
Total current assets
  1,433,000 
  1,613,000 
Property, plant and equipment, net
  663,000 
  718,000 
Patents, net
  118,000 
  123,000 
Right of use asset – operating leases
  11,000 
  0 
Other assets
  21,000 
  21,000 
Total assets
 $2,246,000 
 $2,475,000 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
    
    
Current liabilities
    
    
Accounts payable
 $606,000 
 $359,000 
Accrued expenses and other current liabilities
  534,000 
  449,000 
Right of use liability – operating leases
  12,000 
  0 
Wages payable
  136,000 
  278,000 
Line of credit
  431,000 
  502,000 
Current portion of long-term debt, net of deferred finance costs
  1,079,000 
  237,000 
Total current liabilities
  2,798,000 
  1,825,000 
Long-term debt/other liabilities, net of current portion and deferred finance costs
  0 
  796,000 
Right of use liability – operating leases
  11,000 
  0 
Total liabilities
  2,809,000 
  2,621,000 
COMMITMENTS AND CONTINGENCIES
    
    
Stockholders’ Deficit:
    
    
Common stock
  325,000 
  323,000 
Additional paid-in capital
  21,425,000 
  21,404,000 
Accumulated deficit
  (22,313,000)
  (21,873,000)
Total stockholders’ deficit
  (563,000)
  (146,000)
Total liabilities and stockholders’ deficit
 $2,246,000 
 $2,475,000 
#####
 
 
3

The following information was filed by American Bio Medica Corp (ABMC) on Thursday, November 14, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate American Bio Medica Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by American Bio Medica Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account